Skip to main content
. 2011 Dec 15;40(4):1058–1065. doi: 10.3892/ijo.2011.1299

Figure 4.

Figure 4

Gomisin N up-regulates mRNA expression of DR4 and DR5. (A) HeLa cells were pretreated with gomisin N (100 μM) for 30 min, followed by TRAIL (100 ng/ml) for 3 h. The mRNA levels of DR4 and DR5 were measured by real-time RT-PCR. Data are presented as the mean ± SD of three independent experiments; *P<0.05, **P<0.01 vs. control group, #P<0.05, ##P<0.01 vs. treatment group with TRAIL. (B) HeLa cells were treated with TRAIL for the indicated hours (left). HeLa cells were pretreated with gomisin N for 30 min, followed by TRAIL for the indicated hours (right). The mRNA levels of DR4 and DR5 were measured by real-time RT-PCR. (C) HeLa cells were pretreated with DR4 and/or DR5 blocking antibodies (10 μg/ml) for 30 min, followed by combined treatment with gomisin N for 30 min and then TRAIL for another 24 h. Cell viability was determined by WST-1 assay. Data are presented as the mean ± SD of six independent experiments; **P<0.01 vs. control group; ##P<0.01 vs. combined treatment group with gomisin N and TRAIL. (D) HeLa cells were pretreated with DR4 and/or DR5 blocking antibodies and gomisin N in a similar way and then treated with TRAIL for another 3 h. Cells were collected for detecting the cleavage of caspase-3, caspase-8 and PARP-1 by Western blotting.